Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 11/2016

Open Access 01-10-2016 | Original Article

[68Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis

Authors: Roland Haubner, Armin Finkenstedt, Armin Stegmayr, Christine Rangger, Clemens Decristoforo, Heinz Zoller, Irene J. Virgolini

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2016

Login to get access

Abstract

Purpose

This study was designed to determine safety, tolerability, and radiation burden of a [68Ga]NODAGA-RGD-PET for imaging integrin αvβ3 expression in patients with hepatocellular carcinoma (HCC) and liver cirrhosis. Moreover, metabolic stability and biokinetic data were compiled.

Methods

After injection of 154–184 MBq [68Ga]NODAGA-RGD three consecutive PET/CT scans were acquired starting 8.3 ± 2.1, 36.9 ± 2.8, and 75.1 ± 3.4 min after tracer injection. For metabolite analysis, blood and urine samples were analyzed by HPLC. For dosimetry studies, residence time VOIs were placed in the corresponding organs. The OLINDA/EXM program was used to estimate the absorbed radiation dose.

Results

The radiopharmaceutical was well tolerated and no drug-related adverse effects were observed. No metabolites could be detected in blood (30 and 60 min p.i.) and urine (60 min p.i.). [68Ga]NODAGA-RGD showed rapid and predominantly renal elimination. Background radioactivity in blood, intestine, lung, and muscle tissue was low (%ID/l 60 min p.i. was 0.56 ± 0.43, 0.54 ± 0.39, 0.22 ± 0.05, and 0.16 ± 0.8, respectively). The calculated effective dose was 21.5 ± 5.4 μSv/MBq, and the highest absorbed radiation dose was found for the urinary bladder wall (0.26 ± 0.09 mSv/MBq). No increased uptake of the tracer was found in HCC compared with the background liver tissue.

Conclusions

[68Ga]NODAGA-RGD uptake in the HCCs lesions was not sufficient to use this tracer for imaging these tumors. [68Ga]NODAGA-RGD was well tolerated and metabolically stable. Due to rapid renal excretion, background radioactivity was low in most of the body, resulting in low radiation burden and indicating the potential of [68Ga]NODAGA-RGD PET for non-invasive determination of integrin αvβ3 expression.
Literature
1.
2.
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatology 2012;56:908-43.
3.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.CrossRefPubMed
4.
Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157–64.CrossRefPubMed
5.
Haubner R, Beer AJ, Wang H, Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S86–103.CrossRefPubMedPubMedCentral
6.
Haubner R, Maschauer S, Prante O. PET-Radiopharmaceuticals for Imaging Integrin Expression: Tracers in Clinical Studies and Recent Developments. BioMed research international 2014;871609. doi:10.​1155/​2014/​871609.
7.
Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61–9.CrossRefPubMed
8.
Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, et al. Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005;2:e70. doi:10.​1371/​journal.​pmd.​0020070.
9.
Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the αvβ3-selective tracer 18F-Galacto-RGD in cancer patients. J Nucl Med. 2005;46:1333–41.PubMed
10.
Beer AJ, Haubner R, Wolf I, Goebel M, Luderschmidt S, Niemeyer M, et al. PET-based human dosimetry of 18F-Galacto-RGD, a new radiotracer for imaging αvβ3 expression. J Nucl Med. 2006;47:763–9.PubMed
11.
Knetsch PA, Petrik M, Griessinger CM, Rangger C, Fani M, Kesenheimer C, et al. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression. Eur J Nucl Med Mol Imaging. 2011;38:1303–12.CrossRefPubMed
12.
Cai H, Conti PS. RGD-based PET tracers for imaging receptor integrin αvβ3 expression. J Labelled Compounds Radiopharm. 2013;56:264–79.CrossRef
13.
Jin Y, Chen J, Feng Z, Zhang Z, Fan W, Wang Y, et al. OPN and αvβ3 expression are predictors of disease severity and worse prognosis in hepatocellular carcinoma. PLoS One. 2014;9, e87930.CrossRefPubMedPubMedCentral
14.
Petrik M, Knetsch PA, Knopp R, Imperato G, Ocak M, von Guggenberg E, et al. Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system. Nucl Med Commun. 2011;32:887–95.CrossRefPubMed
15.
Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, et al. Phase I trial of the positron-emitting Arg–Gly–Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879–86.CrossRefPubMed
16.
Doss M, Kolb HC, Zhang JJ, Belanger MJ, Stubbs JB, Stabin MG, et al. Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humans. J Nucl Med. 2012;53:787–95.CrossRefPubMed
17.
Deloar HM, Fujiwara T, Shidahara M, Nakamura T, Watabe H, Narita Y, et al. Estimation of absorbed dose for 2-[F-18]fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med. 1998;25:565–74.CrossRefPubMed
18.
ICRP Publication 62: Radiological Protection in Biomedical Research. In. Oxford, U.K.: Pergamon Press; 1991.
Metadata
Title
[68Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis
Authors
Roland Haubner
Armin Finkenstedt
Armin Stegmayr
Christine Rangger
Clemens Decristoforo
Heinz Zoller
Irene J. Virgolini
Publication date
01-10-2016
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3396-3

Other articles of this Issue 11/2016

European Journal of Nuclear Medicine and Molecular Imaging 11/2016 Go to the issue

Original Article

Effect of adjuvant lithium on thyroxine (T4) concentration after radioactive iodine therapy

Short Communication

Recommended administered activities for 68Ga-labelled peptides in paediatric nuclear medicine

Original Article

A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis

Original Article

18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer

Original Article

Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis

Review Article

Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours